Ongoing cancer research provides one virtue that many cancer sufferers desperately need: Hope. With over 100 types of cancer affecting individuals all over the globe, every bit of progress toward more effective treatment brings us closer to winning the fight against this deadly disease. DelMar Pharmaceuticals Inc. ($DPMI), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, is actively working towards this goal. Their operations and the noteworthy recent clinical trials of one breakthrough anti-cancer drug have positioned them as a likely highlight at one upcoming biotech investor conference.
DelMar Pharmaceuticals announced that they will present at the 14th Annual Bio Investor Forum. The conference, hosted at Larc 55 Hotel in San Francisco, CA, will be held October 20-21, 2015.
On Wednesday, October 21, 2015 at 3:00 p.m. Pacific Time, Jeffrey Bacha, President and CEO of Del Mar will present a corporate overview. The presentation will discuss Del Mar’s current Phase II clinical trial of VAL-083, and the company’s plans to begin clinical trials of the anti-cancer drug for the treatment of small cell lung cancer. A live audio webcast will be available, along with a replay of the webcast that can be accessed two hours after the presentation has concluded.
Del Mar Pharmaceuticalsrevealed positive results from its Phase I/II study of the effects of VAL-083 in patients diagnosed with refractory glioblastoma multiforme (GBM) this past September. VAL-083, a small-molecule chemotherapeutic drug product of Valent Technologies, showed promising results prior to the company’s clinical studies. The US National Cancer Institute proved that VAL-083 was safe and effective in treating lung, brain and cervical cancers in over 40 I and II clinical studies. The drug is currently being administered in China to treat chronic myelogenous leukemia lung cancer.
With a promising clinical trial currently underway, and plans for another, Del Mar Pharmaceuticals continues to not only be a leader in anti-cancer research; but the work of Del Mar continues to yield signs of hope.
For more information about DelMar Pharmaceuticals, visit www.delmarpharma.com.
Disclosure: In the purview of Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention the fact that Equities.com, Inc. may be compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker, broker dealer, investment advisor, analyst, investment banker or underwriter. All profiles are based on information that is available to the public. The information contained herein should not be considered to be all-inclusive and is not guaranteed by Equities.com to be free from misstatement or errors. Readers are reminded to do their own due diligence when researching any companies mentioned on this website.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer